Analysts Set Integer Holdings Co. (NYSE:ITGR) PT at $145.44

Integer Holdings Co. (NYSE:ITGR) has received an average rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $145.44.

Several research firms recently commented on ITGR. Truist Financial raised their price objective on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Benchmark raised their price target on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Citigroup boosted their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and issued a $140.00 target price (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Finally, Bank of America lifted their target price on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 1st.

Institutional Investors Weigh In On Integer

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Contravisory Investment Management Inc. raised its position in Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Integer by 0.8% during the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock valued at $1,579,000 after purchasing an additional 90 shares during the last quarter. Xponance Inc. raised its holdings in shares of Integer by 4.9% during the 2nd quarter. Xponance Inc. now owns 2,112 shares of the medical equipment provider’s stock valued at $245,000 after buying an additional 99 shares in the last quarter. Azzad Asset Management Inc. ADV lifted its position in Integer by 0.9% in the 3rd quarter. Azzad Asset Management Inc. ADV now owns 11,572 shares of the medical equipment provider’s stock worth $1,504,000 after buying an additional 107 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in Integer by 15.5% in the third quarter. TD Private Client Wealth LLC now owns 1,420 shares of the medical equipment provider’s stock worth $185,000 after buying an additional 191 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Stock Down 0.8 %

Shares of NYSE ITGR opened at $134.76 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The stock has a market capitalization of $4.52 billion, a PE ratio of 41.59, a P/E/G ratio of 2.02 and a beta of 1.12. Integer has a one year low of $94.56 and a one year high of $142.76. The business’s fifty day moving average price is $134.70 and its 200-day moving average price is $126.81.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The business had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The company’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.27 earnings per share. On average, equities research analysts anticipate that Integer will post 5.33 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.